Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

10.66

Mkt cap

902M

Volume

656K

High

10.97

P/E Ratio

-6.85

52-wk high

16.99

Low

10.61

Div yield

N/A

52-wk low

6.06

Pomerantz Law Firm is investigating claims on behalf of investors of Liquidia Corporation (NASDAQ:LQDA). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Scotiabank has initiated coverage on Liquidia with a Sector Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 2:22 pm

Liquidia Corp shares rose after the U.S. Supreme Court declined to review rulings, confirming that Liquidia does not infringe on United Therapeutics' patents.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 2:29 pm

On Monday, several US-listed stocks saw significant gains despite a general market downturn. Pfizer's shares rose 4% after Starboard Value acquired a $1 billion stake. Scholar Rock Holding Corp's shares surged 291% following positive clinical trial results. Duckhorn Portfolio's shares climbed 101.3% after reporting strong financial results and announcing an acquisition by Butterfly Equity. Arcadium Lithium gained 40.1% after a potential acquisition approach by Rio Tinto. Vista Outdoor's shares increased 9.8% following a definitive agreement to sell Revelyst.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 2:08 pm

The U.S. Supreme Court has declined to review rulings that invalidate United Therapeutics' patent, confirming that Liquidia does not infringe any valid claims of the patents originally asserted by United Therapeutics. This decision is final and not subject to further appeal.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 2:03 pm

Liquidia (NASDAQ:LQDA) has received diverse ratings from 14 analysts, with most being bullish. The average 12-month price target is $26.36, slightly down from previous estimates. Liquidia faces financial challenges, including a decline in revenue and low profitability metrics.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 5:00 pm

LifeSci Capital has initiated coverage on Liquidia with an Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:04 pm

Liquidia and Pharmosa Biopharm have amended their exclusive licensing agreement for the development and commercialization of sustained release inhaled Treprostinil. This amendment could impact Liquidia's business strategy and market position.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:01 am

A court ruling found that United Therapeutics' interference with the launch of a generic Treprostinil Injection caused over $137M in losses. Liquidia Corporation, in partnership with Sandoz, was affected by this interference.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 1:43 pm

The Nasdaq Composite surged over 200 points, driven by a rise in information technology shares. PureCycle Technologies, BriaCell Therapeutics, and Liquidia Corporation saw significant stock price increases due to positive company announcements. Conversely, Telesis Bio, Rentokil Initial, and Torrid Holdings experienced sharp declines following negative news. U.S. crude oil inventories rose slightly less than expected.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 6:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.